You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 123 No. 6, June 1988 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL ARTICLES
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citing articles on Web of Science (10)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Evaluation of Naloxone Therapy for Escherichia coli Sepsis in the Baboon

Lerner B. Hinshaw, PhD; Linda T. Archer, PhD; Beverly K. Beller; Alvin C. K. Chang; Dayl J. Flournoy, PhD; Richard B. Passey, PhD; Joseph B. Long, PhD; John W. Holaday, PhD

Arch Surg. 1988;123(6):700-704.


Abstract

• This study evaluated the effects of naloxone hydrochloride in the treatment of Escherichia coli–induced shock in baboons. The baboons were studied for 12 hours and monitored for survival times. All baboons were intravenously infused for two hours with E coli and treated as follows: group 1, E coli (control); group 2, E coli plus naloxone hydrochloride, 0.5 mg/kg bolus plus 0.5 mg/kg/h for 9.5 hours; and group 3, E coli plus naloxone hydrochloride, 2.0 mg/kg bolus plus 2.0 mg/kg/h for 3.8 hours. Naloxone was administered after arterial pressure had reached the nadir (more than two hours following initiation of E coli infusion). Mean arterial pressure was supported by the lower dose of naloxone; however, sustained leukopenia and neutropenia were not reversed by its infusion. Naloxone prevented the increase in plasma β-endorphin level and blunted the increase in plasma cortisol level. Despite these effects, naloxone did not prevent multiple-organ disease and did not decrease mortality.

(Arch Surg 1988;123:700-704)



Author Affiliations

From the Oklahoma Medical Research Foundation (Dr Hinshaw), the Veterans Administration Medical Center (Drs Archer, Flournoy, and Passey and Ms Beller), and the University of Oklahoma Health Sciences Center (Dr Passey and Mr Chang), Oklahoma City; and the Walter Reed Army Institute of Research (Drs Long and Holaday), Washington, DC.


Footnotes

Accepted for publication July 8, 1987.

Read before the Federation of American Societies for Experimental Biology, St Louis, April 17, 1986.

Reprint requests to Oklahoma Medical Research Foundation, 825 NE 13th St, Oklahoma City, OK 73104 (Dr Hinshaw).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1988 American Medical Association. All Rights Reserved.